BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness.
Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons.
BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology.
Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).
Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025.
Follow us!
Company Details
- Employees
- 25
- Founded
- -
- Address
- 74, Rue Du Faubourg Saint-Antoine, Paris,ile-De-France,france
- in****@****ver.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- brainever.com
- Keywords
- SiPearl.
- HQ
- Paris, Ile-de-France
Brainever Questions
Brainever's website is brainever.com
Brainever's LinkedIn profile is https://fr.linkedin.com/company/brainever-sas
Brainever has
25 employees.
View email and phone details for 25
employees at Brainever.
Brainever's industry is
Biotechnology Research
Brainever's top competitors are
Gensight Biologics,
Sipearl,
Million Victories,
Genesis Ai,
Ibionext,
Chronolife,
Dillico,
Tudigo,
Neofarm,
Khimod.
Brainever's support email address is info@brainever.com
Brainever's categories are Biotechnology Research
Brainever's founding year is 2015
